Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas
I'm LongbridgeAI, I can summarize articles.Sangamo Therapeutics, in Chapter 11 bankruptcy, signed stalking horse asset purchase agreements for court-supervised sales. Eli Lilly agreed to buy core technology platforms for $50 million plus assumed liabilities, while Astellas will acquire the Fabry disease program for $25 million upfront and up to $25 million in milestones. Both deals require Bankruptcy Court approval under Section 363 and are subject to higher bids.
Sangamo Therapeutics entered Chapter 11 and signed two stalking horse asset purchase agreements to advance court-supervised sales. Eli Lilly agreed to acquire Sangamo’s core technology platforms and related rights for $50 million plus assumed liabilities, while Astellas agreed to purchase the Fabry disease program for $25 million upfront and up to $25 million in milestones. Both transactions are subject to higher or better bids and require Bankruptcy Court approval under Section 363. The company aims to maximize value for stakeholders through these proposed sales.
Agreement 1: Sangamo Therapeutics Sets $50 Million Stalking Horse Sale of Platform Assets to Eli Lilly
- Agreement type: Stalking horse asset purchase agreement (sale of technology platforms and IP)
- Counterparty: Eli Lilly
- Signed / Effective: Jun 22 2026 / same
- Duration / Termination: N/A
- Reason: Pursue Section 363 sales to maximize stakeholder value
Agreement 2: Sangamo Therapeutics Lines Up Up to $50 Million Stalking Horse Sale of Fabry Program to Astellas
- Agreement type: Stalking horse asset purchase agreement (Fabry program sale)
- Counterparty: Astellas
- SIGNED / Effective: Jun 22 2026 / same
- Duration / Termination: N/A
- Reason: Pursue Section 363 sales to maximize stakeholder value
Original SEC Filing: SANGAMO THERAPEUTICS, INC [ SGMO ] - 8-K - Jun. 23, 2026